

JUN 27 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1849
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.K./	855	7,195,761	03-27-2007	Holtzman et al.	
	878	7,189,819	03-13-2007	Basi et al.	
	879	7,179,892	02-20-2007	Basi et al.	
	880	7,014,855	03-21-2006	Schenk	
	881	6,982,084	01-03-2006	Schenk	
	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	866	6,962,984	11-08-2005	Ishiwata et al.	
	784	2005/0110651 A1	06-02-2005	Basi et al.	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	882	6,787,139	09-07-2004	Schenk	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082782 A1	04-29-2004	Basi et al.	
	849	6,727,349	04-27-2004	LaRosa et al.	
	870	2003/0207828 A1	11-06-2003	Ishiwata et al.	
	804	2003/0202972 A1	10-30-2003	James et al.	
	869	2003/0135035 A1	07-17-2003	Shannon	
	871	2003/0092145 A1	05-15-2003	Jira et al.	
	777	6,270,757	08-07-2001	Wame	
	778	6,267,958	07-31-2001	Andya et al.	
	795	6,210,671	04-03-2001	Co	
	867	5,866,129	02-02-1999	Chang et al.	
	860	5,858,981	01-12-1999	Schreiber et al.	
	779	5,770,700	06-23-1998	Webb et al.	
	780	5,744,132	04-28-1998	Wame et al.	
	876	5,731,284	03-24-1998	Williams	
	781	5,385,887	01-31-1995	Yim et al.	
	868	5,245,015	09-14-1993	Fung et al.	
	819	5,227,159	07-13-1993	Miller	

Examiner
Signature

/Daniel Kolker/

Date
Considered

08/28/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 7

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
D.K./	853	EP	921 189	B1	01-12-2005			
	842	EP	1 481 992	A2, A3	12-01-2004			
	786	EP	758 901	B1	02-26-1997			
	787	EP	758 248	B1	02-19-1997			
	802	EP	597 101	A1	05-18-1994			
	848	WO	05/026211	A2, A3	03-24-2005			
	847	WO	04/071408	A2	08-26-2004			
	797	WO	04/055164	A2	07-01-2004			
	846	WO	04/044204	A2, A3	05-27-2004			
	796	WO	03/105894	A1	12-24-2003			
	845	WO	03/072036	A2, A3	09-04-2003			
	799	WO	03/39485	A2	05-15-2003			
	803	WO	03/16466	A2	02-27-2003			
	788	WO	03/15691	A2	02-27-2003			
	798	WO	03/09817	A2	02-06-2003			
	827	WO	02/96937	A2	12-05-2002			
	789	WO	01/05355	A2	01-25-2001			
	813	WO	97/03192	A3	01-30-1997			
	854	WO	95/07301	A1	03-16-1995			
	814	WO	94/00153	A1	01-06-1994			
	821	WO	91/16928	A1	11-14-1991			

Examiner
Signature

/Daniel Kolker/

Date
Considered

08/28/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 3 of 7	Attorney Docket Number	15270J-004747US	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.K./	875	ARD et al., "Scavenging of Alzheimer's Amyloid β -Protein by Microglia in Culture," <u>J. Neuroscience Research</u> , 43:190-202 (1996).	
	790	BALES et al., "Administration of an Anti-APβ Fragment to APP^{V717E} Transgenic Mice Reduces Neuritic Plaque," Abstract P8-898, Page 0567, presented at Poster Session P4. Therapeutics and Therapeutic Strategies: Therapeutic Strategies, Amyloid-Based	
/D.K./	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti- $\text{A}\beta$ antibody," <u>J. Clin. Invest.</u> , 116(3):825-832 (2006).	
	840	BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <u>Free Press</u> , 7/23/01.	
	832	BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <u>Exp. Neurol.</u> , 120(2):245-263 (1993).	
	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <u>Am. J. Public Health</u> , 88:1337-1342 (1998).	
	791	BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive $\text{A}\beta$ Immunotherapy on Their Clearance," <u>Am. J. Pathology</u> , 165(3):987-995 (2004).	
	823	CASELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <u>Functional Neurobiology of Aging</u> , Hof et al., eds., Academic Press (2001).	
	859	COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <u>Society for Neuroscience</u> , abstract, Washington DC, 11/12-16/05.	
	836	DAS et al., "Reduced effectiveness of $\text{A}\beta$ -42 immunization in APP transgenic mice with significant amyloid deposition," <u>Neurobiology of Aging</u> , 22:721-727 (2001).	
	861	DE FELICE et al., " β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <u>Cell Mol. Neurobiol.</u> , 22(5/6):545-563 (2002).	
	862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <u>Blood</u> , 88(1):202-210 (1996).	
Examiner Signature	/Daniel Kolker/		Date Considered 08/28/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
		Attorney Docket Number	15270J-004747US
Sheet	4	of	7

/D.K./	817	DU et al., "α ₂ -Macroglobulin as a β-Amyloid Peptide-Binding Plasma Protein," <u>J. Neurochemistry</u> , 69(1):299-305 (1997).	
	811	European Search Report of 5/22/06 for European Application 06075704.4-2107.	
	812	European Search Report of 5/22/06 for European Application 06075479.3-2107.	
	852	European Search Report of 1/16/07 for European Application 04776252.1-2405.	
	831	FUKUTANI et al., "Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val->Ile) mutation cases: A morphometric investigation," <u>J. Neurologic Sci.</u> , 149:177-184 (1997).	
	873	GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD): From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <u>Autoimmunity Rev.</u> , 5:33-39 (2000).	
	807	HARA et al., "Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <u>J. Alzheimer's Disease</u> , 6:483-488 (2004).	
	792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <u>J. Biol. Chem.</u> , 276(22):18748-18756 (2001).	
	834	KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <u>Biochemistry</u> , 41:922-928 (2002).	
	863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <u>J. Neuropath Exp. Neurol.</u> , 60(3):274-279 (2001).	
	843	KLYUBIN et al., "Anti-Aβ Antibodies Prevent Block of Long-Term Potentiation in the CA1 Area of Rat Hippocampus <i>In Vivo</i> by naturally Produced Aβ Oligomers," <u>Neurobiology of Aging</u> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).	
	794	KOFLER et al., "Immunoglobulin Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <u>J. Clin. Invest.</u> , 82:852-860 (1988).	
✓	826	KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	

Examiner Signature	/Daniel Kolker/	Date Considered	08/28/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
		Attorney Docket Number	15270J-004747US
Sheet	5	of	7

/D.K./	833	KUO et al., "Comparative Analysis of Amyloid- β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains," <u>J. Biol. Chem.</u> , 276(16):12991-12998 (2001).
	816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β -Amyloid," <u>J. Biol. Chem.</u> , 269(38):23403-23406 (1994).
	822	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.
	841	OKIE, S., "Promising Vaccine Targets Ravager of Minds," <u>Washington Post</u> , page A01, 5/8/01.
	808	OKURA et al., "Nonviral A β DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <u>PNAS</u> , 103(25):9619-9624 (2006).
	829	PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development," <u>J. Am. Soc. Exp. Neurotherapeutics</u> , 2:3-14 (2005).
	806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.
	850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.
	872	PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093.
	864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <u>Int. J. Cancer</u> , 55(1):148-152 (1993).
	877	PLUCKTHUN, A., "Mono- and Bivalent Antibody Fragments Produced in <i>Escherichia coli</i> : Engineering, Folding and Antigen Binding," <u>Immunological Reviews</u> , 130:151-188 (1992).
	837	Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," American Academy of Neurology, 5/7/01.
✓	809	QU et al., "A β ₄₂ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <u>J. Neurological Sciences</u> , 244:151-158 (2006).
	838	ROSENBERG, R. N., "The Potamkin Prize for Plaque, Alzheimer's Disease and Related Disorders," pages 1-5.
/D.K./	865	ROSES, A.D., "Apolipoprotein E alleles as risk factors in Alzheimer's disease," <u>Annu. Rev. Med.</u> , 47:387-400 (1996).

Examiner Signature	/Daniel Kolker/	Date Considered	08/28/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 6 of 7	Attorney Docket Number	15270J-004747US	

/D.K./	851	SALDANHA et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <u>Molecular Immunology</u> , 36:709-719 (1999).
	856	SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , (2007).
	818	SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995).
	828	Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05.
	874	SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <u>Biochem. J.</u> , 314:701-707 (1996).
	839	TRAVIS, J., "A Vaccine for Alzheimer's Disease?@," <u>Science News Online</u> , 156(2) pages 1-3 downloaded from internet (1999).
	857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <u>Science</u> , 309:731-734 (2005).
	844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/1/90).
	815	URMONEIT et al., "Cerebrovascular Smooth Muscle Cells Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997).
	835	VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <u>Progress In Neurobiology</u> , 61:305-312 (2000).
	800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003).
V	801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).
	793	ZAMEER et al., "Single Chain Fv Antibodies against 25-36 Peptide Fragment of Amyloid β: Potential Therapeutic for Alzheimer's Disease," Abstract P4.420, Page S593, presented at Poster Session P4: Therapeutics and Therapeutic Strategies Therapeutic Strategies, Amyloid Based
Examiner Signature	/Daniel Kolker/	
Date Considered	08/28/2007	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known		
	Application Number	10/828,548	
	Filing Date	April 19, 2004	
	First Named Inventor	Schenk	
	Art Unit	1649	
	Examiner Name	Kolker, D. E.	
	Attorney Docket Number	15270J-004747US	
Sheet	7	of	7

/D.K./	825	ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <u>Current Protocols in Mol. Biol.</u> , Supp 41, pages 10.15.1 through 10.15.9 (1998).	
/D.K./	810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003).	

Examiner Signature	/Daniel Kolker/	Date Considered	08/28/2007
-----------------------	-----------------	--------------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640